Abstract
Biologics are one of the fastest growing subsets of pharmaceuticals today. In 2016, ten monoclonal antibodies were approved by the FDA for diverse conditions such as psoriasis and cancer. This high number of approvals followed the previous record number of approvals of ten monoclonal antibodies in 2015. Such high approval rate for biologics is a testament to advances in antibody technology and the unique advantage that this class of therapeutics offers. In addition to monoclonal antibodies, other biologics such as antibody-drug conjugates, multi-specific constructs, and antibody-derived modalities are also being considered as viable drug candidates for development. With so many players in the market, it becomes imperative to have an efficient and effective translational approach early on in the drug development process. Clarity on patient-related variables, construct manufacturing considerations, underlying pharmacology and pathophysiology, as well as integration of key translational considerations can accelerate drug development processes, ultimately benefiting patients in need of such therapies. In the previous edition of this book (First Edition), translational considerations for development of antibody-based therapeutics were discussed. This publication deals with topics related to novel and more complex modalities.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Betts AM, Haddish-Berhane N, Tolsma J, Jasper P, King LE, Sun Y, Chakrapani S, Shor B, Boni J, Johnson TR. Preclinical to clinical translation of antibody-drug conjugates using PK/PD modeling: a retrospective analysis of inotuzumab ozogamicin. AAPS J. 2016;18:1101–16.
Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev. 2007;6:120–6.
Hirsch H, Pinheiro E, Ayers M, Lunceford J, Nebozhyn M, Murphy E, Cai M, Ma Y, Sathe M, McClanahan T. Preclinical to clinical translation of anti-PD-1 blockade. J Immunother Cancer. 2015;3:P92.
Hoffmanand LM, Gore L. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE((R)) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol. 2014;4:63.
Li H, Kock K, Wisler JA, Rees WA, Prince PJ, Reynhardt KO, Hsu H, Yu Z, Borie DC, Salinger DH, Pan WJ. Prediction of clinical pharmacokinetics of AMG 181, a human anti-alpha 4 beta 7 monoclonal antibody for treating inflammatory bowel diseases. Pharmacol Res Perspect. 2014;3:e00098.
Mack ET, Snyder PW, Perez-Castillejos R, et al. Using covalent dimers of human carbonic anhydrase II to model bivalency in immunoglobulins. J Am Chem Soc. 2011;133:11701–15.
Mack ET, Bracher PJ, Perez-Castillejos. Thermodynamic analysis to assist in the design of recombinant antibodies. Crit Rev Immunol. 2012;32:503–27.
Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014;19:869–81.
Roopenianand DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.
Sadekar S, Figueroa I, Tabrizi M. Antibody drug conjugates: application of quantitative pharmacology in modality design and target selection. AAPS J. 2015;17:828–36.
Samineni D, Girish S, Li C. Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies. Expert Rev Clin Pharmacol. 2016;9:1557–69.
Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today. 2009;14:298–305.
Tabrizi M, Funelas C, Suria H. Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J. 2010;12:592–601.
Trivedi A, Stienen S, Zhu M, Li H, Yuraszeck T, Gibbs J, Heath T, Loberg R, Kasichayanula S. Clinical pharmacology and translational aspects of bispecific antibodies. Clin Transl Sci. 2017;10:147–62.
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a bispecific T-cell engager (BiTE((R))) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet. 2016;55:1271–88.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ganti, V., Tabrizi, M.A. (2018). Translational Considerations and Challenges: An Overview. In: Tabrizi, M., Bornstein, G., Klakamp, S. (eds) Development of Antibody-Based Therapeutics. Adis, Singapore. https://doi.org/10.1007/978-981-13-0496-5_2
Download citation
DOI: https://doi.org/10.1007/978-981-13-0496-5_2
Published:
Publisher Name: Adis, Singapore
Print ISBN: 978-981-13-0495-8
Online ISBN: 978-981-13-0496-5
eBook Packages: MedicineMedicine (R0)